Israel Englander’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $22.7M | Buy |
376,777
+174,992
| +87% | +$9.72M | 0.01% | 1515 |
|
|
2026
Q1 | $11.7M | Sell |
201,785
-433,271
| -68% | -$20M | ﹤0.01% | 2027 |
|
|
2025
Q4 | $28.5M | Sell |
635,056
-748,951
| -54% | -$31.5M | 0.01% | 1230 |
|
|
2025
Q3 | $55.6M | Buy |
1,384,007
+501,172
| +57% | +$17.7M | 0.02% | 792 |
|
|
2025
Q2 | $27.6M | Buy |
882,835
+648,779
| +277% | +$21.2M | 0.01% | 1267 |
|
|
2025
Q1 | $7.85M | Sell |
234,056
-111,984
| -32% | -$4.25M | ﹤0.01% | 2424 |
|
|
2024
Q4 | $13.6M | Buy |
346,040
+137,014
| +66% | +$5.66M | 0.01% | 1876 |
|
|
2024
Q3 | $8.23M | Buy |
209,026
+33,442
| +19% | +$1.35M | ﹤0.01% | 2374 |
|
|
2024
Q2 | $6.85M | Buy |
175,584
+91,923
| +110% | +$3.67M | ﹤0.01% | 2420 |
|
|
2024
Q1 | $3.6M | Buy |
83,661
+6,696
| +9% | +$308K | ﹤0.01% | 3209 |
|
|
2023
Q4 | $3.55M | Sell |
76,965
-18,528
| -19% | -$655K | ﹤0.01% | 3095 |
|
|
2023
Q3 | $3.26M | Sell |
95,493
-117,845
| -55% | -$4.41M | ﹤0.01% | 3122 |
|
|
2023
Q2 | $8.21M | Sell |
213,338
-8,132
| -4% | -$323K | ﹤0.01% | 2212 |
|
|
2023
Q1 | $7.93M | Sell |
221,470
-373,071
| -63% | -$13.8M | ﹤0.01% | 2187 |
|
|
2022
Q4 | $23.4M | Buy |
594,541
+34,192
| +6% | +$1.25M | 0.01% | 1320 |
|
|
2022
Q3 | $20.2M | Buy |
560,349
+67,658
| +14% | +$2.43M | 0.01% | 1333 |
|
|
2022
Q2 | $15M | Buy |
492,691
+356,365
| +261% | +$10.8M | 0.01% | 1588 |
|
|
2022
Q1 | $4.17M | Buy |
136,326
+45,705
| +50% | +$1.37M | ﹤0.01% | 3128 |
|
|
2021
Q4 | $2.83M | Sell |
90,621
-145,598
| -62% | -$4.35M | ﹤0.01% | 3442 |
|
|
2021
Q3 | $3.61M | Sell |
236,219
-65,529
| -22% | -$1.14M | ﹤0.01% | 3255 |
|
|
2021
Q2 | $5.62M | Sell |
301,748
-41,151
| -12% | -$759K | ﹤0.01% | 2601 |
|
|
2021
Q1 | $6.14M | Sell |
342,899
-73,576
| -18% | -$1.25M | ﹤0.01% | 2358 |
|
|
2020
Q4 | $6.41M | Buy |
416,475
+297,630
| +250% | +$3.48M | ﹤0.01% | 2205 |
|
|
2020
Q3 | $1.32K | Sell |
118,845
-49,151
| -29% | -$578K | ﹤0.01% | 2934 |
|
|
2020
Q2 | $2.11M | Sell |
167,996
-25,573
| -13% | -$325K | ﹤0.01% | 2496 |
|
|
2020
Q1 | $2.19M | Buy |
193,569
+145,855
| +306% | +$2.08M | ﹤0.01% | 1951 |
|
|
2019
Q4 | $626K | Buy |
+47,714
| New | +$502K | ﹤0.01% | 3246 |
|
|
2019
Q2 | – | Sell |
-48,286
| Closed | -$491K | – | 4523 |
|
|
2019
Q1 | $491K | Sell |
48,286
-97,096
| -67% | -$823K | ﹤0.01% | 3279 |
|
|
2018
Q4 | $917K | Buy |
145,382
+62,509
| +75% | +$556K | ﹤0.01% | 2622 |
|
|
2018
Q3 | $1.09M | Buy |
+82,873
| New | +$960K | ﹤0.01% | 2825 |
|
|
2017
Q1 | – | Sell |
-193,674
| Closed | -$1.49M | – | 3892 |
|
|
2016
Q4 | $1.49M | Buy |
+193,674
| New | +$1.56M | ﹤0.01% | 2041 |
|
Other funds holding XENE
ACA
PCH
DCM
JT
Israel Englander's XENE Position: Q2 2026 in Review
Israel Englander increased its Xenon Pharmaceuticals (XENE) stake by 87% in Q2 2026, buying an estimated $9.72M and bringing the position to 376,777 shares worth $22.7M. The position accounts for 0.01% of the portfolio, ranked #1515.
Israel Englander first reported a position in XENE in Q4 2016 and has held it in 31 quarters since. The position peaked at $55.6M in Q3 2025. 314 funds tracked by Wall St. Rank hold XENE as of Q2 2026.
- Israel Englander held 376,777 shares of Xenon Pharmaceuticals worth $22.7M as of Q2 2026.
- Israel Englander bought 174,992 Xenon Pharmaceuticals shares in Q2 2026, an estimated $9.72M.
- Xenon Pharmaceuticals made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1515 holding.
- Israel Englander first reported a position in Xenon Pharmaceuticals in Q4 2016 and has held it in 31 quarters since.
- Israel Englander's Xenon Pharmaceuticals position peaked at $55.6M in Q3 2025.
- 314 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.